ARROWHEAD PHARMACEUTICALS, INC. Foreign Income Tax Expense (Benefit), Continuing Operations
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Foreign Income Tax Expense (Benefit), Continuing Operations of $3.48 million for the 12-month period ending 2022-09-30, per its 10-K filed 2022-11-28.
Discontinued › Expense Statement › Income Tax
us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations · last filed 2022-11-28
- ARROWHEAD PHARMACEUTICALS, INC. foreign income tax expense (benefit), continuing operations for fiscal 2022 was $3.48M.
- ARROWHEAD PHARMACEUTICALS, INC. foreign income tax expense (benefit), continuing operations for fiscal 2021 was $0.00.
| Period end | Foreign Income Tax Expense (Benefit), Continuing Operations 12 month |
|---|---|
| 2022-09-30 | $3.48M 10-K · filed 2022-11-28 |
| 2021-09-30 | $0.00 10-K · filed 2022-11-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |